Insights
Search Results
Client Highlights
7.10.25
Wilson Sonsini Advises Aqtual on $31 Million Series B
On July 10, 2025, Aqtual, a Hayward, California-based precision medicine company, announced the closing of its $31 million Series B financing round. Investors in the oversubscribed round included Bold Capital, the Bold Longevity Growth Fund, Genoa Ventures, Manta Ray Ventures, Yu Galaxy, and others. Wilson Sonsini Goodrich & Rosati advised Aqtual on the transaction.
Client Highlights
4.16.25
Wilson Sonsini Advises Glycomine on $115 Million Series C
On April 16, 2025, Glycomine, a biotechnology company focused on developing transformative new therapies for orphan diseases, announced a $115 million Series C financing round led by CTI Life Sciences Fund, funds managed by abrdn Inc., and Advent Life Sciences, alongside continued investment from existing investors, Novo Holdings, Sanofi Ventures, Abingworth, RiverVest Venture Partners, Sanderling Ventures, Chiesi Ventures, Remiges Ventures, and Asahi Kasei Ventures. Wilson Sonsini Goodrich & Rosati advised Glycomine on the transaction.
News Articles
12.20.24
Priyanka Nawathe and Rebecca Lilley Recognized by Kids in Need of Defense
Wilson Sonsini associates Priyanka Nawathe and Rebecca Lilley were recently recognized by Kids in Need of Defense (KIND) for the month of December as part of the organization’s Boston office “Pro Bono Attorney Spotlight” feature.
Priyanka and Rebecca recently took on their second case for KIND. When they learned additional information from their client that necessitated quickly filing an asylum application, they pivoted, ensuring that they got the application in on time and preserved their client's eligibility. “Their dedication, tenacity, and resourcefulness are truly inspiring, and we are so grateful for their support,” wrote KIND.
Please see below for KIND’s full Q&A with Priyanka and Rebecca:
Why did you take a KIND case?
Priyanka and Rebecca recently took on their second case for KIND. When they learned additional information from their client that necessitated quickly filing an asylum application, they pivoted, ensuring that they got the application in on time and preserved their client's eligibility. “Their dedication, tenacity, and resourcefulness are truly inspiring, and we are so grateful for their support,” wrote KIND.
Please see below for KIND’s full Q&A with Priyanka and Rebecca:
Why did you take a KIND case?
Client Highlights
11.25.24
Wilson Sonsini Advises GI Windows Surgical on $37 Million Series B
On November 20, 2024, Massachusetts-based GI Windows Surgical, a clinical-stage medical device company dedicated to developing the first fundamental breakthrough in anastomoses technology, announced the completion of a $37 million Series B financing round led by Orlando Health Ventures and joined by Rex Health Ventures with participation from existing investors including Johnson & Johnson Innovation–JJDC, JCInvestco, Fred Moll, MD, and an additional strategic investor. Wilson Sonsini Goodrich & Rosati advised GI Windows Surgical on the transaction.
Client Highlights
7.11.24
Wilson Sonsini Advises Fluent BioSciences on Acquisition by Illumina
On July 9, 2024, Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced that it has acquired Fluent BioSciences (Fluent), developer of an emerging and highly differentiated single-cell technology. Wilson Sonsini Goodrich & Rosati advised Fluent on the transaction.
Client Highlights
3.11.24
Wilson Sonsini Advises Bakkt on Concurrent Registered Direct Offerings
On February 29, 2024, Bakkt Holdings, Inc. (Bakkt), a leading crypto services platform, announced its entry into two securities purchase agreements relating to the purchase and sale of up to 57,670,127 shares of the company’s Class A common stock (or pre-funded warrants in lieu of Class A common stock) and accompanying warrants to purchase up to an equal number of shares of the company’s Class A common stock in concurrent registered direct offerings. The purchase price of each share of Class A common stock and accompanying warrant is $0.8670, resulting in aggregate expected gross proceeds of $50 million. Bakkt issued approximately $42.4 million of such securities on March 4, 2024, and will close on the issuance of the incremental approximately $7.6 million of such securities after the company obtains stockholder approval, subject to the satisfaction of other customary closing conditions. Wilson Sonsini Goodrich & Rosati advised Bakkt on the transaction.
Client Highlights
11.29.23
Wilson Sonsini Advises IVIVA on Acquisition by United Therapeutics
In October 2023, United Therapeutics acquired all of the outstanding equity of IVIVA Medical, Inc., a spin-out from the Harvard Stem Cell Institute addressing the chronic shortage of organs available for transplant. IVIVA is developing the IVIVA Kidney, a printed matrix cellularized with a patient’s own cells, which aids in the filtration and reabsorption functions of the native kidney.
Client Highlights
11.17.23
Wilson Sonsini Advises NTx on $47.5 Million Series B
On November 16, 2023, Nature's Toolbox (NTx), a life sciences company building next generation platforms to manufacture RNA and protein, announced the close of a $47.5 million Series B funding round led by RA Capital Management, with strong participation from existing investors Anzu Partners and BlueStone Venture Partners. Wilson Sonsini Goodrich & Rosati advised NTx on the transaction.
Client Highlights
6.20.23
Wilson Sonsini Advises Neuvivo on $11 Million Financing
On June 15, 2023, Neuvivo, a late-clinical stage biopharmaceutical company developing a new treatment for ALS, announced that it has closed an $11 million round of financing led by PrimeStreet Capital. Wilson Sonsini Goodrich & Rosati advised Neuvivo on the transaction.
Client Highlights
4.18.23
Wilson Sonsini Advises Spring Lane Capital on $31 Million Fundraise for Spring Free EV
On April 6, 2023, Spring Free EV, a financial technology company accelerating the adoption of electric vehicles (EVs) through innovative fintech products, announced the completion of a $31 million fundraise that includes a debt facility and a Series A equity investment led by Spring Lane Capital, a $400 million private equity firm focused on providing hybrid capital for sustainable solutions in the energy, food, water, waste, and transportation industries. The financing will enable Spring Free EV to double the number of EVs it has already put on the road by the end of 2023, with the expectation of scaling to tens of thousands of vehicles on the road by 2025. In addition, at full-scale operation, the company expects to cut the upfront costs of utilizing EVs by more than half the current amount.
Client Highlights
3.31.23
Firm Advises Cognito Therapeutics on $73 Million Series B Financing
On March 22, 2023, neurotechnology company Cognito Therapeutics announced a $73 million Series B financing round. The financing was led by FoundersX Ventures with participation from all its existing investors. The round also included support from new investors Alzheimer’s Drug Discovery Foundation (ADDF), Starbloom Capital, IAG Capital and WS Investment Company. Wilson Sonsini Goodrich & Rosati advised Cognito on the transaction.
Client Highlights
3.17.23
Wilson Sonsini Advises GIC on $6.5 Billion Fundraise for Stripe
On March 15, 2023, Stripe, which builds economic infrastructure for the internet, announced it has signed agreements for a Series I fundraise of more than $6.5 billion at a $50 billion valuation. Primary investors include existing Stripe shareholders—Andreessen Horowitz, Baillie Gifford, Founders Fund, General Catalyst, MSD Partners, and Thrive Capital—as well as new investors including GIC, Goldman Sachs Asset and Wealth Management, and Temasek.